<DOC>
	<DOCNO>NCT02472392</DOCNO>
	<brief_summary>The purpose study examine toxicity use allogeneic stem cell transplantation treatment subject relapse refractory ES rhabdomyosarcoma . This nanrandomized two-arm study design determine safety incidence graft versus host disease ( GVHD ) patient relapse , refractory Ewings sarcoma receive relate unrelated , allogeneic stem cell transplant .</brief_summary>
	<brief_title>Study To Examine Toxicity Of Allogeneic Stem Cell Transplantation For Relapsed Or Therapy Refractory Ewings Sarcoma</brief_title>
	<detailed_description>This study examine toxicity use allogeneic stem cell transplantation treatment subject relapse refractory ES rhabdomyosarcoma . Donors consist either HLA identical 9/10 ( A , B , C , DR , DQ ) match related unrelated donor . Specifically , examine toxicity allogeneic stem cell transplant ( SCT ) patient population , related incidence grade 3-4 acute GVHD incidence transplant relate mortality 100 day use follow treatment plan . Rabbit anti-thymocyte globulin ( ATG ; thymoglobulin ) give unrelated donor transplant recipient dose 3 mg/kg/day I.V . 3 consecutive day ( Days -8 to-6 ) . Equine ATG dose 30mg/kg/day may substitute event severe allergic reaction rabbit ATG . Busulfan ( BU ) give dose 0.8 mg/kg IV q 6 hour , 16 dos day -8 -5 . Busulfan dose modify base upon pharmacokinetics data maintain steady state level 600-900 ng/dl . Patients start seizure prophylaxis levetiracetam prior first dose busulfan discontinue 24 hour last dose busulfan . Melphalan give dose 60 mg/m2 I.V . 15-20 min day -4 -2 per Pediatric SCT Standards Practice Manual . Fludarabine give dose 30 mg/m2/day IV 30 minute 5 dos day -8 -4 . Cyclophosphamide give dose 50 mg/kg/day IV 2 hour 4 dos day -5 -2 . Subjects receive tacrolimus short course mycophenolate prohpylactic Therapy incase Acute Graft-versus-Host Disease . The following procedure also complete throughout study . Physical exams medical history Frequent blood test monitor blood count , blood chemistry , liver kidney function Blood test determine exposure various virus , include virus cause hepatitis ( inflammation liver ) , human immunodeficiency virus ( HIV , virus cause AIDS ) cytomegalovirus Pregnancy test female childbearing age Bone Marrow biopsies aspirate Tests monitor lung heart function Evaluations biopsy monitor GVHD X-rays , CT MRI scan tumor measurement 1 , 3 , 6 12 month least annually thereafter . If subject agree participate research study , receive several drug SCT . Various method use administer medication asPO , IV , Central Line placement .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Ewing</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>1 . Patients age 030 year relapse therapy refractory ES , exclude patient brain metastasis . Patients receive prior autologous stem cell transplant eligible . 2 . Related unrelated marrow peripheral blood stem donor must 9/10 10/10 ( HLA A , B , C , DR , DQ ) match recipient 1 . Organ dysfunction : Patients follow level organ system dysfunction eligible : Cardiac : Ejection Fraction &lt; 50 % Renal : Est . Creatinine Clearance &lt; 50* Hepatic : Bilirubin &gt; 3.0 Pulmonary : DLCO &lt; 70 % , patient cooperate pulmonary function testing , O2 saturation &lt; 95 % room air . Performance status : Lansky performance &lt; 70 ; ECOG status &gt; 2 *this base Schwartz formula child le 18 year age , Cockcroft Gault formula , &gt; 18 year . [ 21 , 22 ] 2 . Patients isolated local recurrence tumor ( site primary tumor ) &gt; 1 year complete therapy exclude , patient could cure local therapy alone . 3 As part standard care pretransplant evaluation , subject test exposure viral agent hepatitis B , C , HTLV1/2 , HIV . Subjects test positive HIV may reject candidate transplantation , base clinical judgment stem cell transplant physician</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>EWINGS , SARCOMA</keyword>
</DOC>